It has been recognized that tissue-specific growth factors and angiogenic factors play important roles in the growth of tumors and in the tissue-repair system. In uterine myometrial smooth muscle cells, it has also been reported that the platelet-derived growth factor (PDGF) binds to PDGF receptors and stimulates proliferation. In this paper, we examine whether or not PDGF is able to stimulate production of vascular endothelial growth factor (VEGF) in cultured human myometrial smooth muscle cells. PDGF treatment enhanced immunoreactive VEGF production as well as cell proliferation. Production of VEGF121 and VEGF165 in the cells was detected by reverse transcription-polymerase chain reaction analysis, but the PDGF treatment did not change the ratio of VEGF165 to VEGF121. The effect of PDGF on cell proliferation leveled off at 10 ng/ml, whereas its effect on VEGF production continued to increase linearly at concentrations above 10 ng/ml. Upon treatment of the cells with antibody against VEGF, the cell proliferation increased linearly even at PDGF concentrations above 10 ng/ml. The enhanced [ 3 H]thymidine incorporation by PDGF was abolished by either mitogen-activated protein kinase kinase (MAPKK) inhibitor or protein kinase C (PKC) inhibitor. In contrast, VEGF production was abolished by MAPKK inhibitor, but not by PKC inhibitor. These results indicate that PDGF stimulates both cell proliferation and VEGF production in partly different signal pathways, and thus PDGF might play a role in the physiology and pathology of the myometrium.
Introduction
Tissue organization is known to be maintained by both cellular proliferation and cellular differentiation. The uterine myometrium is a quiescent tissue composed primarily of differentiated smooth muscle cells, but in leiomyomata the smooth muscle cells undergo proliferation. Platelet-derived growth factor (PDGF) is a mitogen for smooth muscle cells and it is found in human tissues predominantly as a heterodimer of PDGF-A and PDGF-B. PDGF has been localized within human uterine smooth muscle cells (HUSMCs) (Rossi et al. 1992 , Mangrulkar et al. 1995 . Moreover, the -receptor for PDGF was also found in the myometrium, and under certain conditions (including in leiomyomata), PDGF is thought to have a crucial role in the proliferation of HUSMCs (Rossi et al. 1992) . Harrison et al. (1995) reported the expression of the mRNA of the angiogenic factor, vascular endothelial growth factor (VEGF), in human uterine smooth muscle, and they speculated that VEGF plays a part in angiogenesis within the tumor and in the surrounding myometrium. PDGF raises VEGF expression in vascular smooth muscle cells (Brogi et al. 1994 , Stavri et al. 1995 . However, little is known of the mechanism by which PDGF induces VEGF secretion. In this study, we show that PDGF can stimulate proliferation and VEGF secretion in HUSMCs and that the cellular organization of tube-like formation in endothelial cells is stimulated by VEGF secreted from PDGF-treated HUSMCs. In addition, our results show that PDGF stimulated both HUSMC proliferation and VEGF production through partly different signal pathways.
Materials and Methods

Human myometrial cell culture
Myometrial tissues were collected from 16 women undergoing hysterectomy at the Tokyo Medical and Dental University. Patients 40-48 years of age (median age, 45 years) were included in this study. None was pregnant and all had regular menstrual cycles. Informed consent was obtained from each patient and the investigation was approved by the local ethical committee of Tokyo Medical and Dental University. Primary myometrial cells from the human myometrium immediately after the hysterectomy were obtained and cultured using the explant method described previously, as modified by us (Chen et al. 1973 , Moss & Benditt 1975 , Kawaguchi et al. 1985 . The myometrial tissue was cut further with a scalpel into 1 mm pieces in calcium-magnesium-free PBS. Two pieces of the tissue were placed in 35 mm Petri dishes (Becton Dickinson Labware, Franklin Lakes, NJ, USA) and incubated at 37 C/5% CO 2 in air with Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Rockville, MD, USA) or phenol-red-free DMEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (JRH, Lenexa, KS, USA). The medium was changed every 3 days. After becoming confluent, cells were subcultured. They were transferred to other 10 cm Petri dishes by using calcium-magnesium-free PBS supplemented with 0·05% trypsin/EDTA (Life Technologies/ Dojindo, Kumamoto, Japan). Cells were studied from the 1st to the 8th passage.
HUSMCs were seeded at sub-confluence in a 24-well FALCON plate (Becton Dickinson Labware) in DMEM for 24 h, then washed and incubated in serum-free DMEM for 24 h. The media were removed and the cells incubated for 24 h in serum-free DMEM containing 0-50 ng/ml recombinant human PDGF-BB (homodimer of PDGF-B) (Sigma, St Louis, MO, USA), 20 ng/ml VEGF (human recombinant VEGF165) (Pepro Tech, London, UK) or 0-100 nM 17 -estradiol (Sigma). Some cells were incubated in the presence of an additional 3 µg/ml VEGF-neutralizing antibody (IBL, Gunma, Japan). Cells were preincubated for 30 min in the presence of either 100 µM mitogen-activated protein kinase kinase (MAPKK) inhibitor (PD 098059; Biomol, Plymouth Meeting, PA, USA) or 5 µM protein kinase C (PKC) inhibitor (GF 109203X; Sigma) and were then treated with PDGF (Toullec et al. 1991 , Alessi et al. 1995 , Pang et al. 1995 .
[ 3 H]thymidine incorporation
The proliferation of HUSMCs and human umbilical vein endothelial cells (HUVECs) after incubation for 24 h in serum-free DMEM in the presence or absence of PDGF or VEGF was determined by [ 3 H]thymidine incorporation. [ 3 H]thymidine (Amersham, Buckinghamshire, UK) was added at a concentration of 1 µCi/ml for each well and incubated for 2 h. The cultures were washed with calcium-magnesium-free PBS. Cells were solubilized in 500 µl 0·15 N NaOH for 2 h and neutralized in 35 µl 10% CH 3 COOH. After the addition of 5 ml PICO-FLUORTM 40 (Packard Instruments, Meriden, CT, USA), their radioisotope content was determined with a TRI-CARB 2750 TR/LL liquid scintillation counter (Packard Instruments).
Enzyme-linked immunosorbent assay (ELISA)
Secreted VEGF proteins in cultured medium from HUSMCs after incubation for 24 h in serum-free DMEM in the presence or absence of PDGF or 17 -estradiol were determined by using the Quantikine human VEGF ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. This assay employs a murine monoclonal antibody against VEGF and the quantitative sandwich enzyme immunoassay technique. It recognizes both natural and recombinant human VEGF and detects concentrations in the range 15·6-1000 pg/ml.
Reverse transcription-polymerase chain reaction (RT-PCR)
The expression of VEGF isoforms was detected using RT-PCR. Serum-starved, sub-confluent cells in 10 cm Petri dishes were incubated for 24 h with (20 ng/ml) or without PDGF. Total RNA was isolated from myometrial smooth muscle cells by using the Catrimox 14TM RNA isolation kit (TaKaRa, Tokyo, Japan). A RT-PCR was performed with an RNA PCR kit (AMV Version 2.1 (TaKaRa). Total RNA (1 µg) was reverse-transcribed using Random 9-mers for 1 cycle of 30 C for 10 min, 55 C for 30 min, 99 C for 5 min and 5 C for 5 min. The PCR was performed with primers from exon 1 (sense, 5 -TGCCTTGCTGCTCTACCTCC-3 ) and exon 8 (antisense, 5 -TCACCGCCTCGGCTTGTCAC-3 ) of VEGF. The PCR consisted of 35 cycles of 94 C for 0·5 min, 64 C for 0·5 min and 72 C for 1·5 min. The PCR products were separated on a 1·5% agarose gel and viewed with ethidium bromide staining.
Immunofluorescence staining and image analysis of VEGF receptors (KDR and Flt-1)
HUSMCs and HUVECs were used for immunofluorescence staining. Cells were cultured after incubation for 24 h in serum-free DMEM, washed twice with PBS, fixed with 2% formaldehyde, and washed three times with calcium-magnesium-free PBS. After blocking with calcium-magnesium-free PBS containing 10% FBS, anti-KDR antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-Flt-1 antibody (Santa Cruz Biotechnology) was applied at a 1:50 dilution for 60 min at room temperature. After the cells had been washed three times with calcium-magnesium-free PBS, fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin G (Sigma) was applied at a 1:50 dilution for 60 min at room temperature. Fluorescence image analysis was performed with an interactive laser cytometer (ACAS570; Meridian Instruments, Okemos, MI, USA).
In vitro angiogenesis assay (tube formation)
An experiment on tube formation was performed with a modification of the method of Hayashi et al. (1991) .
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4 bovine endothelial cells in 0·5 ml MEM (Life Technologies) containing 5% FBS were plated on 0·5 ml type I collagen gel (Koukenn, Tokyo, Japan) in a 24-well plate and incubated for 24 h. After the medium had been aspirated, the cells were overlaid with 0·5 ml type I collagen gel, then with 250 µl MEM containing 5% FBS and 250 µl of 6 types of medium: (1) DMEM containing 10% FBS with 20 ng/ml VEGF (human recombinant VEGF165); (2) DMEM containing 10% FBS without VEGF; (3) culture medium of HUSMCs after incubation for 2 days in DMEM containing 10% FBS with 20 ng/ml PDGF (conditioned medium); (4) the same as medium (3) but without PDGF; (5) the same as medium (3) but with the addition of 3 µg/ml VEGF-neutralizing antibody (IBL); (6) the same as medium (4) but with the addition of 3 µg/ml VEGF-neutralizing antibody. After incubation for 2 days, morphological changes were observed with a phase-contrast photo-microscope (LH50A; Olympus, Tokyo, Japan).
Western blot analysis
The active form of p42/p44 mitogen-activated protein kinase (MAPK) protein and p42/p44 MAPK protein were detected with a Western blot analysis. Serum-starved, sub-confluent cells in 10-cm Petri dishes were incubated for 5 min with (10 ng/ml) PDGF, without PDGF or with VEGF (50 ng/ml). HUSMCs were homogenized and the solution was clarified by centrifugation. The proteins in the supernatant were separated by SDS-PAGE (10% gel), using 25 µg total protein in each lane. The electrophoresed proteins were transferred to a nitrocellulose membrane. After blocking with 3% BSA, an anti-active form of p42/p44 MAPK protein antibody (Promega, Madison, WI, USA) at a 1:5000 dilution or an anti-p42/p44 MAPK protein antibody (Santa Cruz) at a 1:1000 dilution was applied. The signal was visualized using a horseradish peroxidase-linked secondary antibody (Amersham), at a 1:5000 dilution, and enhanced chemiluminescence (ECL; Amersham).
Statistical analysis
The results are expressed as means ... Statistical analyses were performed with ANOVA followed by Tukey's test or Dunnett's test. Tukey's test was used to compare two treatments, and Dunnett's test was used to compare control and treated cells. A value of P<0·05 was considered statistically significant. All of the experiments were repeated at least three times.
Results
Effect of PDGF on HUSMC proliferation and VEGF production in HUSMCs
PDGF stimulated DNA synthesis in the cultured HUSMCs in a dose-dependent manner. At 10 ng/ml, PDGF induced an approximately 1·5-fold increase in [ 3 H]thymidine incorporation in HUSMCs compared with the control, and at higher doses the effect of PDGF plateaued (Fig. 1a) . The stimulatory effect of PDGF on cell proliferation was confirmed by the increase in cell number (control: 42·2 0·9 10 3 /well; PDGF: 56·3 2·3 10 3 /well). Because myometrial smooth muscle in ewes showed immunostaining for VEGF (Reynolds et al. 1998) , we investigated whether PDGF affected VEGF secretion from HUSMCs. We measured the content of VEGF in cultured media from cells after incubation for 24 h in serum-free DMEM with various doses of PDGF. At concentrations The cultures were treated with PDGF for 24 h in serum-free DMEM, with recombinant human PDGF-BB at concentrations from 1 ng/ml to 50 ng/ml, or with vehicle (control). Data are expressed as means S.E.M. *P<0·05 compared with the control. **P<0·05 compared with the control and 5 ng/ml PDGF. ***P<0·05 compared with the control, 5 ng/ml PDGF, and 10 ng/ml PDGF. ****P<0·05 compared with the control, 5 ng/ml PDGF, 10 ng/ml PDGF, and 20 ng/ml PDGF.
above 5 ng/ml, PDGF induced VEGF secretion in a dose-dependent manner (Fig. 1b) . In contrast to cell proliferation, VEGF secretion increased linearly with the dose of PDGF. PDGF at 10 ng/ml induced a 2·3-fold increase in VEGF secretion, and at 50 ng/ml it induced a 3·8-fold increase relative to the control, respectively.
However, treatment of HUSMCs with 17 -estradiol, which is known as an inducer of VEGF production in endometrium (Shifren et al. 1996 , Huang et al. 1998 , failed to stimulate VEGF secretion at any of the doses used in this experiment (data not shown).
By using RT-PCR, we observed the expression of VEGF isoforms in HUSMCs cultured in the presence or absence of PDGF (Fig. 2) . The two most common VEGF isoforms, VEGF121 and VEGF165, were detected. The presence of 403 bp and 535 bp amplicons confirmed the presence of mRNA for VEGF121 and VEGF 165. PDGF-stimulated cells showed the same pattern of VEGF isoforms when compared with the unstimulated cells.
Effect of VEGF on proliferation of HUSMCs
To examine the effect of VEGF on the functions of HUSMCs, the expression of VEGF receptors (Flt-1 and KDR) was first measured by the indirect immunofluorescence method. The expression of VEGF receptors was analyzed quantitatively using a laser cytometer (ACAS570; Meridian Instruments, Okemos, MI, USA) (Fig. 3) . Although the fluorescence intensities in HUSMCs were lower than those in HUVECs, it showed that the expression of KDR was detectable in HUSMCs.
The treatment of HUSMCs with 20 ng/ml VEGF failed to increase the [ (Fig. 4a) . It is interesting that treatment of the cells with antibody against VEGF raised the cell proliferation linearly even at PDFG concentrations above 10 ng/ml (Fig. 4b) .
In vitro angiogenesis induced by conditioned medium of HUSMCs
To investigate whether the VEGF secreted from HUSMCs was functionally active, the conditioned medium of HUSMCs in the presence or absence of PDGF was applied to an in vitro tube-formation assay system. As previously described, when bovine endothelial cells were cultured between type I collagen for 2 days with VEGF, a tube-like formation was produced (Fig. 5D) (Hayashi et al. 1991) . The cellular organization of the tube-like formation was slightly stimulated by the conditioned medium of HUSMCs (Fig. 5B) , and was stimulated even more by the cultured medium of PDGF-treated HUSMCs (Fig. 5E ).
The stimulatory effect of both conditioned media was abolished by the simultaneous addition of a neutralizing antibody against VEGF (Fig. 5C and F) . These results indicate that PDGF stimulates the secretion of functionally active VEGF proteins.
Involvement of MAPK and PKC in the stimulatory effects of PDGF on proliferation and VEGF secretion in HUSMCs
To determine which signal pathways are involved in the stimulatory effects of PDGF on the proliferation of, and VEGF secretion in, HUSMCs, the cell lysates were subjected to Western blot analysis for p42/p44 MAPK and phosphorylated MAPK (an active form of MAPK). HUSMCs were placed in serum-free DMEM for 24 h and then pulsed with PDGF for 5 min. Cell lysates were immunoblotted with an antibody that recognized phosphorylated MAPK. Incubation of HUSMCs with 50 ng/ml human recombinant VEGF165 did not cause any change in the basal level, but treatment with 10 ng/ml PDGF resulted in an increase in phosphorylation of MAPK (Fig. 6 ). In contrast, the amount of immunoreactive MAPK was not changed by any of these treatments. Next, to determine if the activation of MAPK mediates the proliferation and VEGF secretion in HUSMCs induced by PDGF, the cells were treated with PD098059, a specific inhibitor of MAPKK. In addition, we also examined the effect of GF109203X (a specific PKC inhibitor) on the proliferation and VEGF secretion induced by PDGF. [ 3 H]thymidine incorporation was significantly reduced by both PD098050 and GF109203X, suggesting that the MAPK and PKC pathways are involved in the proliferation of HUSMCs induced by PDGF (Fig. 7a) . In contrast, VEGF secretion was also reduced to the basal level by PD098050 but was not significantly reduced by GF109203X, suggesting that the MAPK pathway is the predominant pathway in PDGF-induced VEGF secretion (Fig. 7b) .
Discussion
PDGF, fibroblast growth factor, epidermal growth factor and insulin-like growth factor have been postulated to act as mitogens of myometrial smooth muscle cells, and to play roles in the pathogenesis of certain conditions, e.g. in leiomyomata (Rossi et al. 1992 , Tang et al. 1994 , Mangrulkar et al. 1995 . The expression of their growthfactor receptors has been also demonstrated in HUSMCs (Fayed et al. 1989 , Rossi et al. 1992 , Tang et al. 1994 . In this work, we selected PDGF as a mitogen of HUSMCs because it is known to be the most powerful among the mitogens of smooth muscle cells. The PDGF receptor appears in two forms, each having different affinities, designated as the -and -types. Immunohistochemical studies indicated that primary HUSMCs cultures expressed the -receptor of PDGF, but not the -receptor (Rossi et al. 1992) . The -type receptor binds to PDGF-BB with high affinity and to PDGF-AB (heterodimer of PDGF-A and PDGF-B) with low affinity. Therefore, in this work PDGF-BB was used. Treatment of HUSMCs with PDGF-BB significantly raised [ 3 H]thymidine incorporation, but at concentrations above 10 ng/ml the stimulatory effect leveled off. This dose-dependency of PDGF is consistent with the results of Rossi et al. (1992) , who demonstrated that PDGF-AB stimulated DNA synthesis of HUSMCs, with maximal stimulation at 10 ng/ml PDGF-AB, and that no significant stimulation occurred at higher concentrations. It is widely accepted that treatment of cells with PDGF triggers phosphorylation cascades that lead to activation of MAPK and PKC (Kazlauskas & Cooper 1988 , Choudhury et al. 1993 , De & Iyengar 1994 , Lubinus et al. 1994 . As expected, PDGF activated MAPK (Fig. 6) , and the enhanced [ 3 H]thymidine incorporation by PDGF was abolished by inhibitors of either MAPKK or PKC (Fig. 7a) .
The conditioned medium of HUSMCs cultured with PDGF enhanced the tube-forming activity of bovine endothelial cells cultured within type I collagen. The stimulatory effect of the conditioned medium was abolished by anti-VEGF antibody (Fig. 5) . Therefore, we carried out RT-PCR and detected the production of VEGF 121 and VEGF 165 in the cells (Fig. 2) . There are five isoforms of VEGF (from the number of amino acids), namely VEGF 121, 145, 165, 189 and 206. Among them, VEGF 121, 165 and 189 were expressed in many kinds of cells, and VEGF 206 was detectable in fetal liver (Keck et al. 1989 , Houck et al. 1991 , Tischer et al. 1991 . VEGFs 121, 165 and 189 were detected in human myometrium (Charnock et al. 1993 , Harrison et al. 1995 . Charnock et al. (1993) also detected VEGF 145. Our data were not coincident with these results. The difference in expression may be due to the origin of the samples, as cultured myometrial smooth muscle cells were used in the present work, whereas myometrial tissue was used in the other studies. Treatment of HUSMCs with PDGF did not change the ratio of VEGF 121 to VEGF 165, in spite of the fact that the production of immunoreactive VEGF was enhanced by PDGF.
The dose-dependent curves linking DNA synthesis and VEGF production stimulated by PDGF were different; that is, the effect of PDGF on cell proliferation leveled off at 10 ng/ml, whereas its effect on VEGF production continued to increase linearly at concentrations above 10 ng/ml. This difference leads to us to the following two hypotheses: (1) VEGF released by the treatment of PDGF at concentrations above 10 ng/ml negatively regulates the proliferation of HSUMCs induced by PDGF; and (2) the different signaling pathways are involved in the stimulatory effects of PDGF on DNA synthesis and VEGF production. The first hypothesis might be supported by the data from the treatment with anti-VEGF antibody (Fig. 4b) . In the recent study, the treatment of sinusoidal endothelial cells with VEGF induced apoptosis via PKC activation (M Shibuya, personal communication). Therefore, though it is possible that VEGF prevents cell growth or survival, further studies are necessary to reveal the mechanism by which VEGF downregulates PDGF-induced cell proliferation in HUSMCs.
Several papers have demonstrated the involvement of PKC and MAPK in PDGF-induced cell proliferation (Choudhury et al. 1993 , De & Iyengar 1994 , Lubinus et al. 1994 . Our data also support the involvement of PKC and MAPK in the proliferation of HUSMCs induced by PDGF-BB. Recently, Milanini et al. (1998) have shown that p42/p44 MAPK plays a key role in the expression of VEGF. PKC is involved in the induction of VEGF expression by phorbol myristate acetate (Hata et al. 1999) . It is possible that among several PKC isomers, PKC activation and translocation are important in VEGF expression. It has been reported that PDGF activated PKC in human dermal fibroblasts (Xu et al. 1996) . A Western blot analysis showed that PKC and PKC were the dominant PKC isomers expressed in human myometrial cells (Tertrin et al. 1999) . These reports suggest that VEGF production induced by PDGF is dependent on PKC activation. However, in our experiment, treatment of HUSMCs with GF 109203X failed to abolish the production of VEGF induced by PDGF. This inhibitor was previously shown to inhibit PKC activity (Xu et al. 1996) . The reason why PKC is not involved in PDGF-induced VEGF production in HUSMCs is unclear, but our experiment indicates that PDGF raises VEGF secretion predominantly through MAPK activation. Reynolds et al. (1998) reported that 17 -estradiol enhanced VEGF mRNA expression in ovariectomized ewes in vivo. Therefore, to confirm this phenomenon, HUSMCs were treated with 17 -estradiol, and VEGF protein levels in the medium were measured. However, we did not observe a stimulatory effect of 17 -estradiol on VEGF secretion. The different observations are probably due to a difference in the experimental conditions.
In conclusion, PDGF stimulates the proliferation of, and VEGF secretion in, HUSMCs, and angiogenesis via 
